Tourmaline Bio Inc (TRML)

Jun 13, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by California State Teachers Retirement System - Defense World

Jun 13, 2025

Jun 12, 2025

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings - Defense World

Jun 12, 2025

Jun 10, 2025

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 10, 2025

Jun 09, 2025

Tourmaline Bio Releases Updated Corporate Presentation - TipRanks

Jun 09, 2025

Jun 06, 2025

Tourmaline Bio Elects Directors and Ratifies Auditor - TipRanks

Jun 06, 2025

Jun 06, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE - Defense World

Jun 06, 2025

Jun 04, 2025

Nuveen Asset Management LLC Has $1.55 Million Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 04, 2025

Jun 03, 2025

BNP Paribas Financial Markets Reduces Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 03, 2025

Jun 02, 2025

Jane Street Group LLC Cuts Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 02, 2025

Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $291,000 Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 01, 2025

May 31, 2025

Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 31, 2025

May 30, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 30, 2025

May 29, 2025

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN

May 29, 2025

May 28, 2025

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey

May 28, 2025

May 27, 2025

H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India

May 27, 2025

May 27, 2025

H.C. Wainwright maintains $50 target on Tourmaline Bio stock - Investing.com

May 27, 2025

May 27, 2025

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 27, 2025

May 26, 2025

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World

May 26, 2025

May 25, 2025

Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com

May 25, 2025

May 23, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World

May 23, 2025

May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia

May 21, 2025

May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria

May 21, 2025

May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria

May 21, 2025

May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com

May 21, 2025

May 21, 2025

Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter

May 21, 2025

May 21, 2025

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com

May 21, 2025

May 21, 2025

Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus

May 21, 2025

May 20, 2025

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha

May 20, 2025

May 20, 2025

Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga

May 20, 2025

May 20, 2025

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive

May 20, 2025

May 20, 2025

Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks

May 20, 2025

May 20, 2025

Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News

May 20, 2025

May 20, 2025

Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com

May 20, 2025

May 20, 2025

Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com

May 20, 2025

May 20, 2025

Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks

May 20, 2025

May 20, 2025

Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq

May 20, 2025

May 20, 2025

Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha

May 20, 2025

May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com

May 20, 2025

May 20, 2025

Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia

May 20, 2025

May 20, 2025

Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus

May 20, 2025

May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire

May 20, 2025

May 20, 2025

Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan

May 20, 2025

May 19, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa

May 19, 2025

May 19, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia

May 19, 2025

May 19, 2025

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times

May 19, 2025

May 19, 2025

Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq

May 19, 2025

May 19, 2025

Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan

May 19, 2025

May 16, 2025

Tower Research Capital LLC TRC Increases Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 16, 2025